Cardiogen (25mg)

Cardiogen is a synthetic pentapeptide bioregulator composed of the amino acid sequence Ile-Glu-His-Gly-Thr. Unlike larger peptides, it contains no disulfide bridges and is categorized as a short tissue-specific peptide developed for targeted research into cardiovascular health. Initially designed as a myocardial-supporting compound, Cardiogen has been studied for its potential to influence gene expression linked to cardiac function, tissue repair, and mitochondrial energy regulation.

Research has explored Cardiogen’s application in addressing conditions associated with cardiac stress, myocardial degeneration, and age-related decline in heart performance. Studies suggest Cardiogen may enhance the functional integrity of heart tissue by modulating gene activity, supporting protein synthesis, and reducing oxidative stress in cardiomyocytes. Additionally, it has shown potential to improve mitochondrial efficiency—key to ATP production and endurance—making it a compelling focus in cardiac and metabolic research.

Unlike traditional cardiovascular agents, Cardiogen does not act through receptor-mediated pathways but is believed to exert its effects epigenetically, through direct interaction with DNA regions in cardiac cells. This gene-regulatory mechanism sets it apart from other peptides, providing a novel, targeted approach to tissue-specific repair without triggering systemic hormonal responses or immune reactivity.

Due to its minimalist structure and specific activity profile, Cardiogen has drawn interest in the scientific community for its potential role in regenerative cardiology, aging-related heart support, and mitochondrial optimization. These characteristics position Cardiogen as a promising candidate in the expanding field of peptide-based bioregulatory research.